Join a walk for Crohn's & Colitis.
Register for a walk near you!
Train for a half marathon while raising funds for crucial research. Teams
forming now -- find yours today!
Infliximab Does Not Boost Mortality Risk with Crohn's Disease
NEW YORK (Reuters Health) - In patients with Crohn's disease, the tumor necrosis factor alpha antagonist infliximab does not increase mortality compared to use of conventional treatments, registry data suggest.
It did seem to increase patients' risk of serious infection, but higher risks were seen with prednisone, narcotic painkillers, and more severe disease. In an August 14th online paper in the American Journal of Gastroenterology, Dr. Gary R. Lichtenstein of the University of Pennsylvania in Philadelphia and colleagues note that all therapies for Crohn's disease can have adverse side effects. But early use of immunomodulators along with biological therapies has been shown to induce more rapid remission.
In an earlier study, the researchers found that mortality rates across treatments seem to be similar. In the current study the team extended their evaluation of registry data from a mean of about 1.9 years to 5.2 years. In all, 6,273 patients were involved, roughly half of whom (54.5%) received infliximab. The remainder received other treatments only.
More patients in the infliximab group had moderate to severe disease (30.6% vs 10.7%) or severe-to-fulminant disease (2.5% vs 0.6%). In the year before enrollment, more infliximab-treated patients required surgical intervention (17.4% vs 13.6%) and hospitalization (14.2% vs 8.8%). They were also more likely to need prednisone, immunomodulators and narcotic analgesics.
The mortality rate was similar in infliximab-treated patients and the control group. In multivariate analyses, mortality was linked with prednisone, narcotic analgesics and age, but not with infliximab or immunomodulator treatment.
A higher incidence of infections in general was observed in the infliximab-treated patients relative to patients receiving other treatments only. However, infliximab-treated patients had more severe disease at registry entry and also were more likely to be using other immunosuppressive agents or prednisone. In addition, there was no evidence of an increase in the occurrence of serious infections with an increasing number of infliximab infusions. Factors independently associated with serious infections included moderate to severe disease activity (hazard ratio, 2.24), narcotic analgesic treatment (HR 1.98), prednisone therapy (HR 1.57) and infliximab treatment (HR 1.43).
The researchers believe it is "likely that infliximab lessened the disease burden and thus counterbalanced any mortality risk that might have been associated with other causes such as serious infection."
Also, they point out, "There has been no indication that infliximab is associated with an increased risk of neoplasia or an increased risk of fetal malformation."
Dr. Lichtenstein did not respond to requests for comments.
Am J Gastroenterol 2012
- FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis
- Changing the Research Paradigm with a Patient-Powered Network
- Expanding IBD Research Through Collaboration
- Largest Microbiome Study on Newly Diagnosed Patients Gives Insight Into Crohn’s Disease and Shows Antibiotic Treatment May Worsen Disease
- Two Studies Identify Promising New Drug for IBD Patients